Skip to content

Study of correlation among serum high molecular weight adiponectin relevant factors in newly diagnosed type 2 diabetic patients with metabolic syndrome

Study of correlation among serum high molecular weight adiponectin relevant factors in newly diagnosed type 2 diabetic patients with metabolic syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OCH-14005062
Enrollment
Unknown
Registered
2014-07-18
Start date
2014-08-10
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes with metabolic syndrome

Interventions

newly diagnosed type 2 diabetes with metabolic syn:Measuring physical index, blood specimens
newly diagnosed type 2 diabetes without metabolic:Measuring physical index, blood specimens

Sponsors

Department of Endocrinology, Affiliated Hospital of Jiangsu University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. T2DM subjects: The criteria of diagnosis of type 2 diabetes recommended by WHO in 1999 were adopted, these newly diagnosed T2DM subjects had fasting plasma glucose levels more than 7.0mmol/L and 2h OGTT glucose levels more than 11.1mmol/L; The diagnosis of MetS was based on the global consensus of MetS according to the 2005 International Diabetes Federation. Patients must have central obesity (Chinese standard: male waist circumference more than 90 cm, female waist circumference more than 80 cm) and any 2 of the following 4 factors to make the diagnosis: 1) TG more than 1.7 mmol/L; 2) HDL-C less than 1.03 mmol/L for men and less than 1.29 mmol/L for women; 3) increasing fasting plasma glucose (FPG more than 5.6 mmol/L); 4) high blood pressure (systolic blood pressure higher than 130 mmHg or diastolic blood pressure higher than 85 mmHg); 2. Normal control: healthy person.

Exclusion criteria

Exclusion criteria: T2DM subjects who were treated with oral hypoglycemic agents were excluded to avoid the possible confounding effects of anti-diabetic medications. T1DM, individuals with gestational diabetes, active hepatitis/liver cirrhosis, chronic renal failure on hemodialysis, congestive heart failure or other known major disease were precluded from the study.

Design outcomes

Primary

MeasureTime frame
high-molecular-weight adiponectin;OGTT;netrin-1;

Secondary

MeasureTime frame
hs-CRP;insulin releasing test;HbA1c;BMI;blood lipid profiles;blood pressure;age;

Countries

China

Contacts

Public ContactYuan Guo-yue
yuanguoyue@hotmail.com+86 13505289352

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026